Connect with us

Business

Eli Lilly’s next-generation obesity drug delivers strong weight loss, reduces knee pain in late-stage trial  

Published

on

Eli Lilly’s next-generation obesity drug delivers strong weight loss, reduces knee pain in late-stage trial  


The Eli Lilly logo appears on the company’s office in San Diego, California, U.S., Nov. 21, 2025.

Mike Blake | Reuters

Eli Lilly on Thursday said its next-generation obesity drug delivered what appears to be the highest weight loss yet in a late-stage trial while reducing knee arthritis pain, clearing the first of several upcoming studies on the weekly injection. 

The highest dose of the drug helped patients with obesity and a type of knee arthritis lose an average of 23.7% of their body weight at 68 weeks, when analyzing all participants, including those who discontinued treatment. When evaluating only patients who stayed on the drug, the highest dose delivered 28.7% weight loss on average.

The company said some patients lost so much weight that they decided to drop out of the trial.

“It’s incredible,” said Dr. Caroline Apovian, co-director of the Center for Weight Management and Wellness at Brigham and Women’s Hospital. “Now, we have a drug that rivals the weight loss benefits of surgery.”

Apovian said Eli Lilly appears to be positioning the drug strategically for people with severe obesity, or a body mass index above 35 or 40. She noted that the company said 84% of patients in the trial had a BMI above that number in the trial.

Shares of Eli Lilly rose more than 3% on Thursday.

It is the first late-stage data on retatrutide, which works differently from existing injections and appears to be more effective. Eli Lilly is betting big on retatrutide as the next pillar of its obesity portfolio after its weight loss injection Zepbound and its upcoming pill. But it’s still unclear when the drug could enter the market.

It’s a critical part of the drugmaker’s plan to maintain its market share majority over Novo Nordisk in the booming market for weight loss and diabetes drugs. Some analysts estimate the segment could be worth about $100 billion by the 2030s.

Retatrutide also met the trial’s other main goal of reducing pain from knee osteoarthritis – a common condition that wears down the joint’s cartilage and leads to pain and stiffness – by up to 62.6% on average when analyzing all patients, based on a widely used survey. More than 1 in 8 patients who took the drug were completely free from knee pain by the end of the trial, Eli Lilly said. 

One concern with current weight loss drugs is that they can lead to the loss of lean muscle mass. But Apovian said the results show that in adults with severe obesity, you can improve physical function with retatrutide. 

The results appear to surpass Wall Street’s expectations. In a note ahead of the findings, BMO Capital Markets analyst Evan Seigerman said his base-case assumption was for the drug to show weight loss of around 20% to 23%, with at least a 50% reduction in knee pain.

The company believes retatrutide “could become an important option for patients with significant weight loss needs and certain complications, including knee osteoarthritis,” Kenneth Custer, president of Lilly Cardiometabolic Health, said in a statement. 

In a note Thursday, JPMorgan analyst Chris Schott said retatrutide’s tolerability data, or how well patients handle the treatment, is “somewhat worse vs Zepbound, though not surprising, in our view.”

Roughly 18% of patients on the highest dose of the drug stopped treatment due to side effects, compared with 4% of those in the placebo group. Eli Lilly said those dropout rates were “highly correlated” to patients’ starting body mass index and included discontinuations due to “perceived excessive weight loss.” 

Among those with a BMI of 35 or higher who took highest dose, 12% stopped treatment. Schott said that number is closer to the dropout rates seen in trials on Eli Lilly’s weight loss drug Zepbound and Novo Nordisk‘s obesity injection Wegovy.

In a separate note on Thursday, BMO’s Seigerman said discontinuation rates “appear to highlight the speed and strength of weight loss was excessive for some patients with lower BMI.” But he said, “all in results are impressive.”

Around 43% of patients on the highest dose experienced nausea, while roughly 33% and 20.9% had diarrhea and vomiting, respectively. More than 1 in 5 patients on the highest dose also experienced dysesthesia, which is an unpleasant nerve sensation. The company said it was generally mild for patients and rarely led to them discontinuing treatment.

The study, called TRIUMPH-4, didn’t solely focus on weight loss, meaning that other trials specifically designed for that outcome could produce different or higher results. Eli Lilly expects to report findings from seven additional phase three trials on the drug by the end of 2026. 

More CNBC health coverage

Dubbed the “triple G” drug, retatrutide works by mimicking three hunger-regulating hormones – GLP-1, GIP and glucagon – rather than just one or two like existing treatments. That appears to have more potent effects on a person’s appetite and satisfaction with food than other treatments.

Tirzepatide, the active ingredient in Zepbound, mimics GLP-1 and GIP. Novo Nordisk’s semaglutide, the active ingredient in Wegovy, mimics only GLP-1.

Higher doses of tirzepatide helped patients with obesity lose roughly 20.9% of their body weight on average in late-stage studies, when analyzing all patients regardless of discontinuations.

As Eli Lilly establishes an edge in the space, its chief rival, Novo Nordisk, is racing to catch up. In March, Novo Nordisk said it agreed to pay up to $2 billion for the rights to an early experimental drug from the Chinese pharmaceutical company United Laboratories International. 

Novo Nordisk’s newly acquired drug is a clear potential competitor to retatrutide because it similarly uses a three-pronged approach to promoting weight loss and regulating blood sugar. But Novo Nordisk’s treatment is much earlier in development, meaning it will take several years before it reaches patients.



Source link

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Business

RBI Holds 879.6 Tonnes Of Gold As Prices Surge Amid Global Uncertainty

Published

on

RBI Holds 879.6 Tonnes Of Gold As Prices Surge Amid Global Uncertainty


New Delhi: The Reserve Bank of India, as on March 31 this year, held 879.58 metric tonnes of gold as compared to 822.10 metric tonnes as on March 31, 2024, reflecting an increase of 57.48 metric tonnes, the Parliament was informed on Monday.

These gold holdings contribute to strengthening confidence in the Indian rupee and the overall external stability of the economy, Minister of State for Finance Pankaj Chaudhary told the Lok Sabha in a reply to a question.

To questions about the surge in gold and silver prices in the domestic market, he said that domestic prices of precious metals like gold and silver are primarily determined by their prevailing international prices (in US dollar terms), the exchange rate of the Indian rupee against the US dollar and applicable tariffs.

Add Zee News as a Preferred Source


The recent surge in prices is largely attributable to heightened geopolitical tensions and uncertainty over global growth, which have boosted safe-haven demand, including substantial gold purchases by central banks and major institutions worldwide.

The minister said that the recent rally in gold prices may have differential effects across states or population groups, depending upon the degree of socio-cultural and economic reliance on these precious metals.

“They serve a dual role — not only as a consumption item but also as an investment avenue, as they are considered safe assets for hedging against uncertainties,” he said.

Thus, an increase in the price of gold or silver positively influences household wealth, as the notional value of existing gold or silver holdings appreciates, he added. Chaudhary further stated that the prices of precious metals are determined by the market, and the government is not involved in the price fixation.

However, the government, as a relief measure for consumers, lowered customs duty on gold imports from 15 to 6 per cent in July 2024.

The government introduced measures such as the Gold Monetisation Scheme (GMS), Gold exchange‑traded funds (ETFs) and Sovereign Gold Bond Scheme to reduce the demand for physical gold and to mobilise idle domestic gold, so that part of the demand is met from local stocks rather than fresh imports, thereby reducing external vulnerability and price pressures.

“The RBI and government regulation of bullion imports through nominated agencies, banks and refineries improve traceability, reduce grey‑market channels and help domestic prices more smoothly track global benchmarks rather than react to shortages or speculative spikes,” the minister said.



Source link

Continue Reading

Business

Mercosur hurdle: French objections and farm protests freeze EU trade deal; Brussels faces credibility test – The Times of India

Published

on

Mercosur hurdle: French objections and farm protests freeze EU trade deal; Brussels faces credibility test – The Times of India


France’s last-minute opposition and mounting farmer protests are threatening to derail the European Union’s long-delayed free-trade agreement with South America’s Mercosur bloc, raising fresh doubts over whether the pact can be signed this year, AP reported.Angry European farmers, fearing cheaper agricultural imports and tougher competition, have taken to the streets in Brussels just as EU negotiators were hoping to close a deal that has taken nearly 25 years to negotiate. The agreement involves the 27-country EU and five Mercosur nations — Brazil, Argentina, Uruguay, Paraguay and Bolivia — and would gradually remove duties on most goods traded between the two blocs over 15 years.The accord, agreed in principle a year ago, still needs approval from all EU member states and the European Parliament. EU officials had planned for European Commission President Ursula von der Leyen and European Council President António Costa to sign the deal in Brazil on December 20, but growing resistance now threatens that timeline.French Prime Minister Sébastien Lecornu said on Sunday that the current deal was “unacceptable” and that the “conditions have not been met” for EU leaders to authorise its signing this week, effectively seeking a delay that could push the decision to 2026 or later. While acknowledging steps taken by the European Commission to protect farmers and tighten food safety checks, Lecornu said France remained unconvinced.Poland, Austria, the Netherlands and France fear Mercosur exporters could undercut EU farmers who operate under stricter labour, environmental and sanitary rules, including pesticide restrictions, analysts told AP. France has been pressing for “mirror clauses” that would require Mercosur producers to meet the same standards — demands that have not been fully accepted.Alicia Gracia-Herrero, a senior fellow at the Brussels-based Bruegel Institute, said the standoff exposed limits to the EU’s political unity and global influence. “If we cannot get this done even with (US President Donald) Trump’s pressure, what can you expect from the EU?” she said, warning that further delays could undermine Brussels’ credibility in talks with partners such as Indonesia and India.The deal comes at a sensitive time for the EU, which has been seeking to diversify trade ties after Trump imposed tariffs of 15% on most EU imports earlier this year, AP reported. Brussels sees the Mercosur pact as a strategic counterweight to aggressive trade tactics by both the US and China.European Commission spokesperson Olof Gill said the bloc is pushing to conclude the agreement by year-end, arguing it would strengthen the EU’s geopolitical standing. “We’re talking about bringing together two of the world’s biggest trading blocs,” he said, citing cooperation on climate, economic security and reform of the global rules-based order.Agriculture remains central to the dispute. The EU exported 235.4 billion euros ($272 billion) worth of agricultural goods in 2024, and critics warn the deal could hurt local dairy and beef producers and cause environmental damage. Supporters counter that it would save businesses about $4.26 billion in duties annually and open markets for products ranging from French wine to German pharmaceuticals and Brazilian minerals.To calm opposition, the European Commission has proposed safeguards, including mechanisms allowing farmers to trigger investigations if Mercosur imports are priced at least 10% below EU products, tighter border inspections for banned pesticides, and reforms to distribute agricultural subsidies more equitably.These measures, however, have failed to ease French concerns or quell farmer anger. Agricultural unions are again planning demonstrations in Brussels as EU leaders meet later this week, underlining the political risks surrounding a deal that was once seen as a cornerstone of the bloc’s trade strategy.



Source link

Continue Reading

Business

‘Can a dead economy grow at 8.2%?’: FM Sitharaman rebuts Trump remark in Lok Sabha; cites IMF ratings upgrade – The Times of India

Published

on

‘Can a dead economy grow at 8.2%?’: FM Sitharaman rebuts Trump remark in Lok Sabha;  cites IMF ratings upgrade – The Times of India


Finance Minister Nirmala Sitharaman on Monday cited India’s strong growth and sovereign rating upgrades to counter claims that the country was a “dead economy”, telling the Lok Sabha that such upgrades would not have been possible if the economy were weak, PTI reported.Responding to Opposition members who sought the government’s reaction to US President Donald Trump’s description of India as a “dead economy”, Sitharaman said India remains the fastest-growing major economy, recording 8.2% growth in the September quarter.“The economy in the last 10 years has transitioned from external vulnerability to external resilience,” the minister said while replying to the Supplementary Demands for Grants for 2025-26 in the House.“Every institution is raising our growth outlook for this year and the forthcoming year. There are clear expressions (from the IMF) recognising India’s growth and no dead economy gets a credit rating upgrade by DBRS, S&P and R&I,” Sitharaman said.Trump had made the “dead economy” remark in July while expressing disappointment with India’s decision to continue buying oil from Russia. Sitharaman said data and assessments by global institutions contradicted that characterisation.“The economy today has moved from fragility to fortitude,” she said.“So somebody said something somewhere, however important that somebody is, we should not depend on that but rely on data available within the country and also data coming from elsewhere. Rely on data,” she told Opposition members.“Can a dead economy grow at 8.2%? Can a dead economy get credit rating upgrades?” Sitharaman asked.The Reserve Bank of India last week raised its GDP growth projection for FY26 to 7.3% from 6.8% earlier. India grew 8.2% in the September quarter and 7.8% in the June quarter.On concerns raised over the International Monetary Fund’s assessment of India’s national accounts — including Gross Domestic Product (GDP) and Gross Value Added (GVA) — Sitharaman said India’s overall grading remains unchanged at the median rating of ‘B’.She said the IMF had flagged the outdated base year for national accounts and suggested rebasing. “So to say that there has been a downgrade by IMF is misleading the House. For this year, IMF gave B for overall statistics,” she said, adding that India has remained the fastest-growing major economy for the fourth consecutive year despite the pandemic.Sitharaman also addressed concerns over public debt, saying India’s debt-to-GDP ratio rose to 61.4% after Covid but was brought down to 57.1% by 2023-24 due to policy measures taken by the central government.“By this year-end, I expect it to come down to 56.1%,” the finance minister said.



Source link

Continue Reading

Trending